Bone marrow transplants, a University of Minnesota medical breakthrough, celebrate 50th anniversary

As doctors reflected on the anniversary of one of the U's signature achievements, they expressed equal excitement about the progress ahead.

August 31, 2018 at 1:01AM
MINNEAPOLIS/USA - July 23: Entrance to the campus of the University of Minnesota. The University of Minnesota is a university in Minneapolis and St. Paul, MN and the 6th largest univerity in the USA. July 23, 2012. ORG XMIT: MIN1505261330310624 ORG XMIT: MIN1510071124370054 ORG XMIT: MIN1601201325070229
Fifty years ago, the world’s first successful transplant of donor bone marrow was performed at the University of Minnesota. (The Minnesota Star Tribune)

Fifty years after the world's first successful transplant of donor bone marrow, performed at the University of Minnesota, doctors marvel at the progress it inspired in the field of regenerative medicine.

Originated as a treatment for the rare "bubble boys," whose lives were threatened by simple infections, bone marrow and related transplants now occur more than 50,000 times a year to grow new immune systems in patients with aggressive cancers and blood disorders.

In the intervening years, doctors have learned more about protecting recipients from transplant-related complications, which has driven up the survival rate substantially, and how to match bone marrow donors and recipients by their DNA and blood types.

"We're not at a stage where it's easy," said Dr. Daniel Weisdorf, senior research adviser for the U's Center for International Blood and Marrow Transplant Research. "We're at a stage where it's much safer and easier than it use to be. And that's exciting."

As doctors reflected last week on the anniversary of one of the U's signature achievements, they expressed equal excitement about the progress ahead. Two "CAR T" therapies have been approved in the past year to coax the T-cells in patients' existing immune systems to fight certain cancers, acute lymphoblastic leukemia in children and advanced lymphomas in adults.

Now researchers at the U and other institutions are testing second-generation versions that are "tunable," meaning they can be turned off if they are too harsh or have eradicated tumors, and turned back on if cancer returns.

It won't take 50 years to reach the next milestones, Weisdorf said. "That's not even 20 years away."

Researchers also are reporting progress in finding new targets on the surfaces of cancer cells that will trigger T-cells to attack. They also are working with "NK," or natural killer, cells, which play innate roles in the immune system and can attack tumors without those triggers.

Weisdorf said the ability of these new therapies to coax patient's existing immune systems might replace the use of transplants to grow new systems in many cancer patients. But bone marrow transplants will continue to have a role.

Marking the 50th anniversary was equally important, he said, because it gave the U a chance to inspire today's patients with stories of transplant recipients who are alive 25 to 30 years later. When such patients come to his clinic, Weisdorf said, he never misses a chance to take them around the waiting room and share their stories. "I make a lot of noise," he said. " 'Look at this! 25 years!' It's pretty incredible."

Jeremy Olson • 612-673-7744

about the writer

about the writer

Jeremy Olson

Reporter

Jeremy Olson is a Pulitzer Prize-winning reporter covering health care for the Star Tribune. Trained in investigative and computer-assisted reporting, Olson has covered politics, social services, and family issues.

See Moreicon